Overview
- At the International AIDS Conference in late July 2026, UNAIDS reported that international HIV aid fell by more than $1.5 billion in 2025 to about $7.3 billion, the lowest level in nearly two decades.
- The drop reflects sharp reductions by the United States under President Donald Trump and long-term declines from European governments, with U.S. contributions still accounting for roughly three quarters of state aid last year.
- Funding shortfalls triggered immediate disruptions: WHO merged units and cut about 30 percent of staff, UNAIDS pared staff by more than half, some clinics have closed, and prevention services in parts of sub‑Saharan Africa largely stopped.
- Access to new medicines is a flashpoint because high prices and limited rollouts threaten care expansion; Merck has allowed generics for a new drug while aid groups are pressing Gilead over the cost and restricted availability of a twice‑yearly injectable prevention drug.
- UN officials warned that without renewed donor, national government, and pharmaceutical action the gains in infections and deaths made over decades could be undone and children’s treatment gaps will widen since only slightly more than half of HIV‑positive children now receive preventive medicines.